Alembic Pharma

BSE: 533573 | NSE: APLLTD
Alembic Pharma (CIN: L24230GJ2010PLC061123) operates in the Pharmaceuticals industry and has been listed in the stock market since 20 Sep 2011. It currents trades on NSE with symbol APLLTD and on BSE with scrip code 533573.
The registered office of the company is Alembic Road, , Vadodara, Gujarat - 390003.

The management team of Alembic Pharma is led by Chirayu Amin who is the Chairperson. Other members of the management team consist of Chirayu Ramanbhai Amin (Designation:Executive Director-Chairperson related to Promoter), Pranav Chirayu Amin (Designation:Executive Director-MD), Shaunak Chirayu Amin (Designation:Executive Director-MD), Ashok Kumar Barat (Designation:Non-Executive - Independent Director), Jai Shishir Diwanji (Designation:Non-Executive - Independent Director), Manish Santoshkumar Kejriwal (Designation:Non-Executive - Independent Director), Geeta Amit Goradia (Designation:Non-Executive - Independent Director), Sujit Jaysukh Bhayani (Designation:Non - Executive Independent Director), Bhayani Sujit Jaysukh (Designation:Non-Executive - Independent Director), Raj Kumar Baheti (Designation:Non-Executive - Non Independent Director), Ajay Kumar Desai (Designation:Sr. Vice President-Finance), G Krishnan (Designation:Chief Financial Officer), Manisha Saraf (Designation:Company Secretary & Compliance Officer), .

The price and other financial information of Alembic Pharma is as below -

BSE 832.25 2.6 (0.31%)

BSE

832.25 2.6 (0.31%)
Volume: 4,892.00
M. Cap: 16,311.69
P/E: 23.66
Prev. Close: 829.65
52 Wk

NSE 1229 37.05 (3.11%)

NSE

1229 37.05 (3.11%)
Volume: 77,427.00
M. Cap: 16,355.91
P/E: 23.66
Prev. Close: 830.10
52 Wk

Stock Price Chart

F&O Data

Shareholding Pattern

Category No. of shares Percent(%)
Promoters 13,70,81,813 69.74
Pledge 0 0.00
Foreign Institutions 83,61,504 4.26
Financial Institutions 3,17,47,127 16.14
NBFC and Mutual Funds 1,60,83,228 8.18
Others 1,93,72,680 9.86
Total 21,26,46,352 108.18

Financial Data

Consolidated
Figures in crore 2026 2025 2024
Net Sales 7,344.90 6,672.08 6,228.63
Operating Profit 1,106.13 1,064.53 960.69
Other Income 54.66 56.30 28.30
Interest 93.63 78.77 56.19
Depreciation 318.55 278.58 272.67
Profit Before Tax 693.95 707.18 631.83
Tax 23.12 125.17 16.01
Profit After Tax 670.83 582.01 615.82
Share Capital 39.31 39.31 39.31
Reserves 5,635.50 5,151.63 4,778.89
Net Worth 5,674.81 5,190.94 4,818.20
Loans 1,763.03 1,381.81 622.67
Gross Block 4,896.98 4,117.32 3,875.19
Investments 140.88 127.21 93.02
Cash 202.70 90.10 126.57
Debtors 1,466.30 1,399.79 1,024.84
Net Working Capital 3,527.06 3,083.36 2,276.78
Operating Profit Margin (%) 15.06 15.95 15.42
Net Profit Margin (%) 9.13 8.72 9.89
EPS 34.33 29.68 31.33
Dividend (%) 600.00 550.00 550.00
Dividend Payout 216.22 216.21 157.25
Standalone
Figures in crore 2026 2025 2024
Net Sales 6,651.38 6,032.63 5,874.06
Operating Profit 1,051.62 962.14 1,029.84
Other Income 55.90 60.75 504.88
Interest 86.51 76.47 54.47
Depreciation 311.00 277.08 271.14
Profit Before Tax 654.11 608.59 704.23
Tax 13.69 105.47 37.75
Profit After Tax 640.42 503.12 666.48
Share Capital 39.31 39.31 39.31
Reserves 5,575.95 5,155.43 4,869.60
Net Worth 5,615.26 5,194.74 4,908.91
Loans 1,350.99 1,318.24 601.50
Gross Block 4,628.65 4,100.64 3,859.15
Investments 271.40 259.56 226.68
Cash 28.74 20.85 26.49
Debtors 1,603.75 1,480.67 1,340.12
Net Working Capital 3,183.03 2,902.72 2,223.71
Operating Profit Margin (%) 15.81 15.95 17.53
Net Profit Margin (%) 9.63 8.34 11.35
Earning Per Share (Rs) 32.58 25.60 33.91
Dividend (%) 600.00 550.00 550.00
Dividend Payout 216.22 216.22 0.00
Dividend Declared (₹)
The company has declared dividend 5 times between 17 Aug 2022 and 29 Jul 2026, totaling Rs. 52.00 so far. The most recent dividend was declared on 29 Jul 2026 for Rs. 12.

Financial Data Graph

The peers of Alembic Pharma are LUPIN, ALKEM and SPARC. You can get more detailed information on those company by clicking on the respective names.

* The above data is collected from public sources and we do not guarantee the accuracy of the same.*

Popular Comments

No comment posted for this article.